A Primary 3D Culture Model for the High Throughput Ex-vivo Modeling of Ovarian Cancer Metastasis

Inventor(s):

    SUMMARY

    • Current high throughput screens for ovarian cancer drug discovery use monolayer cell culture on plastic, and problematically cannot accurately model the cross communication between the cancer cells and the tumor microenvironment that occur in vivo. The lack of effective models for ovarian cancer drug screening is responsible for the high attrition rate from screen hits to potent in vivo drug leads.
    • The inventors developed a heterotypic, 3D organotypic culture system that enables evaluation of adhesion, migration, invasion, and proliferation of ovarian cancer cells in the context of in in vivo-like tumor microenvironment. The model is assembled using primary human omental fibroblasts, mesothelial cells, and extracellular matrices, on top of which cancer cell lines are cultured. 
    • The invention is a 3D organotypic culture system that recapitulates the surface histology of the abdominal peritoneum, the primary site of ovarian cancer metastasis. The model is compatible with high throughput screening in both a 384 and 1536 well format for drug discovery campaigns.
    • The inventors optimized and validated the culture system with multiple ovarian cancer cell lines (HeyA8, SKOV3ip1, Tyk-nu) by using the model to screen a 44,000-compound library for inhibitors of ovarian cancer metastasis, adhesion and migration. The lead compounds were validated in vivo with mouse models of ovarian cancer (see 19-T-011 for compounds).

     

    FIGURE

    (A) Overview of the 3D ovarian cancer culture model showing positioning of all cell types in the model and the ability to use the model to evaluate the efficacy of drug compounds. (B) Fluorescent images of the 3D HITS assay with fluorescent labeled mesothelial cells (blue) and fibroblasts (red) with SKOV3ip1 ovarian cancer cells (green). Scale bar represents 100um. Z-axis reconstruction of optical sections with orthogonal view of maximum intensity shown (45um scale).

     

    ADVANTAGES

    ADVANTAGES

    • Models peritoneal metastasis (main site of ovarian cancer metastasis)
    • Models in vivo activity in library screens
    • Model accounts for fibroblast contribution to metastasis
    • Compatible with high throughput screening
    • Applicable to other cancers that metastasize to the peritoneal cavity (gastric, pancreatic, endometrial)

     

    APPLICATIONS

    • High throughput drug discovery (metastatic ovarian cancer)
    • Research tool
    • Personalized medicine

     

    PUBLICATIONS

     

    TECH DETAILS

    Published
    9/15/2019

    Reference ID
    18-T-575

    Have Questions?

    Michael Hinton

    Contact Michael Hinton, Manager, Technology Marketing, who can provide more detail about this technology, discuss the licensing process, and connect you with the inventor.

    This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of products and services, assist with our promotional and marketing efforts.

    Accept
    [%Analytics%]